Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors

Published:2022-12-01 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Thomas Austin R.,Liu Cynthia,Tong Yi T.,Tan Dongfeng,Altan Mehmet,Siddiqui Bilal A.,Shatila Malek,Khan Anam,Thomas Anusha S.,Wang Yinghong

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04499-9.pdf

Reference37 articles.

1. Abdel-Wahab N, Shah M, Lopez-Olivo M et al (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 168(2):121–130

2. Abu-Sbeih H, Ali F, Naqash A et al (2019) Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol 37(30):2738–2745

3. Abu-Sbeih H, Faleck D, Ricciuti B et al (2020) Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 38(6):576–583

4. Abu-Sbeih H, Zou F, Dutra B et al (2021) Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis. J Clin Oncol 39(15):2642

5. Ahmed M, Francis G (2018) Pembrolizumab-induced microscopic colitis. Am J Gastroenterol 113(4):629–630

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors;Alimentary Pharmacology & Therapeutics;2024-04-08

2. Vedolizumab;Reactions Weekly;2023-08-05

3. Collagenous Colitis in a Patient With Gastric Cancer Who Underwent Chemotherapy;Cureus;2023-05-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3